Researchers led by Philip LoGrasso from The Scripps Research Institute in Florida have identified new potent and highly selective c-jun-N-terminal kinase (JNK) inhibitors. The JNKs are a class of enzymes that are linked to oxidative stress and cell death in Parkinson’s disease. Evidence also exists of their involvement in the pathophysiology of ALS. The compounds are brain penetrant and improve mitochondrial function in cell-based assays, and the researchers are now working on improving the oral bioavailability of these promising new drugs.
Click here to read more.